{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-346856","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2026-08-12T20:10:19+00:00","discovered_at":"2026-08-12T20:11:00.291705+00:00","generated_at":"2026-08-12T20:11:21.787204+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kura Q2: KOMZIFTI revenue $9.1M, majority share in NPM1-m AML menin class","bullets":["KOMZIFTI net product revenue $9.1M, up 57% QoQ; ~115 new patient starts, up 35% QoQ.","Achieved majority share of new patient starts in R/R NPM1-m AML menin inhibitor class.","EHA 2026 KOMET-007: CRc 96% (NPM1-m) and 90% (KMT2A-r) with 600mg ziftomenib+7+3; 12-mo OS 94%/71%.","Net loss $68.3M; cash $519.0M plus $180M anticipated Kyowa Kirin payments fund through 2028 pivotal readout.","Darlifarnib combo data: 67% ORR pancreatic, 50% NSCLC in KRAS G12C; ccRCC ORR up to 50%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-346856","json":"https://secwatch.observer/filing/0001193125-26-346856.json","markdown":"https://secwatch.observer/filing/0001193125-26-346856.md","text":"https://secwatch.observer/filing/0001193125-26-346856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526346856/0001193125-26-346856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526346856/kura-20260812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:11:21.787204+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}